{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:46:56Z","timestamp":1787867216111,"version":"build-2784847793"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosci. Bull."],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12264-025-01515-z","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T16:20:10Z","timestamp":1760372410000},"page":"419-438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PET Molecular Imaging of the Endocannabinoid System in Psychiatric Disorders"],"prefix":"10.1007","volume":"42","author":[{"given":"Chunyi","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peili","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chentao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1633-2988","authenticated-orcid":false,"given":"Mei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4084-5150","authenticated-orcid":false,"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2288-8034","authenticated-orcid":false,"given":"Yan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"1515_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/jamapsychiatry.2019.3272","volume":"77","author":"CF Zorumski","year":"2020","unstructured":"Zorumski CF. JAMA psychiatry: Best of 2019. JAMA Psychiatry 2020, 77: 117.","journal-title":"JAMA Psychiatry"},{"key":"1515_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s43657-023-00134-w","volume":"4","author":"X Han","year":"2024","unstructured":"Han X, Zeng Y, Shang Y, Hu Y, Hou C, Yang H. Risk of cardiovascular disease hospitalization after common psychiatric disorders: Analyses of disease susceptibility and progression trajectory in the UK biobank. Phenomics 2024, 4: 327\u2013338.","journal-title":"Phenomics"},{"key":"1515_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/wps.20388","volume":"16","author":"AF Jorm","year":"2017","unstructured":"Jorm AF, Patten SB, Brugha TS, Mojtabai R. Has increased provision of treatment reduced the prevalence of common mental disorders? Review of the evidence from four countries. World Psychiatry 2017, 16: 90\u201399.","journal-title":"World Psychiatry"},{"key":"1515_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/ije\/dyu038","volume":"43","author":"Z Steel","year":"2014","unstructured":"Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, et al. The global prevalence of common mental disorders: A systematic review and meta-analysis 1980\u20132013. Int J Epidemiol 2014, 43: 476\u2013493.","journal-title":"Int J Epidemiol"},{"key":"1515_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41392-022-00918-y","volume":"7","author":"X Xiong","year":"2022","unstructured":"Xiong X, Chen S, Shen J, You H, Yang H, Yan C, et al. Cannabis suppresses antitumor immunity by inhibiting JAK\/STAT signaling in T cells through CNR2. Signal Transduct Target Ther 2022, 7: 99.","journal-title":"Signal Transduct Target Ther"},{"key":"1515_CR6","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/bph.12411","volume":"171","author":"N Murataeva","year":"2014","unstructured":"Murataeva N, Straiker A, Mackie K. Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. Br J Pharmacol 2014, 171: 1379\u20131391.","journal-title":"Br J Pharmacol"},{"key":"1515_CR7","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/febs.12152","volume":"280","author":"N Ueda","year":"2013","unstructured":"Ueda N, Tsuboi K, Uyama T. Metabolism of endocannabinoids and related N-acylethanolamines: Canonical and alternative pathways. FEBS J 2013, 280: 1874\u20131894.","journal-title":"FEBS J"},{"key":"1515_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1748-1716.2011.02280.x","volume":"204","author":"JR Savinainen","year":"2012","unstructured":"Savinainen JR, Saario SM, Laitinen JT. The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol (Oxf) 2012, 204: 267\u2013276.","journal-title":"Acta Physiol (Oxf)"},{"key":"1515_CR9","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","volume":"79","author":"HC Lu","year":"2016","unstructured":"Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry 2016, 79: 516\u2013525.","journal-title":"Biol Psychiatry"},{"key":"1515_CR10","doi-asserted-by":"publisher","first-page":"9472","DOI":"10.3390\/ijms22179472","volume":"22","author":"H Lowe","year":"2021","unstructured":"Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The endocannabinoid system: A potential target for the treatment of various diseases. Int J Mol Sci 2021, 22: 9472.","journal-title":"Int J Mol Sci"},{"key":"1515_CR11","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1046\/j.1460-9568.1999.00847.x","volume":"11","author":"G Marsicano","year":"1999","unstructured":"Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999, 11: 4213\u20134225.","journal-title":"Eur J Neurosci"},{"key":"1515_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0306-4522(97)00436-3","volume":"83","author":"K Tsou","year":"1998","unstructured":"Tsou K, Brown S, Sa\u00f1udo-Pe\u00f1a MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83: 393\u2013411.","journal-title":"Neuroscience"},{"key":"1515_CR13","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/j.1476-5381.2010.00819.x","volume":"160","author":"MS Garc\u00eda-Guti\u00e9rrez","year":"2010","unstructured":"Garc\u00eda-Guti\u00e9rrez MS, P\u00e9rez-Ortiz JM, Guti\u00e9rrez-Ad\u00e1n A, Manzanares J. Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br J Pharmacol 2010, 160: 1773\u20131784.","journal-title":"Br J Pharmacol"},{"key":"1515_CR14","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1073\/pnas.1600013113","volume":"113","author":"DG Gee","year":"2016","unstructured":"Gee DG, Fetcho RN, Jing D, Li A, Glatt CE, Drysdale AT, et al. Individual differences in frontolimbic circuitry and anxiety emerge with adolescent changes in endocannabinoid signaling across species. Proc Natl Acad Sci USA 2016, 113: 4500\u20134505.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1515_CR15","doi-asserted-by":"publisher","first-page":"17078","DOI":"10.3390\/molecules191117078","volume":"19","author":"F Fezza","year":"2014","unstructured":"Fezza F, Bari M, Florio R, Talamonti E, Feole M, Maccarrone M. Endocannabinoids, related compounds and their metabolic routes. Molecules 2014, 19: 17078\u201317106.","journal-title":"Molecules"},{"key":"1515_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.biopsych.2015.12.021","volume":"80","author":"CH Demers","year":"2016","unstructured":"Demers CH, Drabant Conley E, Bogdan R, Hariri AR. Interactions between anandamide and corticotropin-releasing factor signaling modulate human amygdala function and risk for anxiety disorders: An imaging genetics strategy for modeling molecular interactions. Biol Psychiatry 2016, 80: 356\u2013362.","journal-title":"Biol Psychiatry"},{"key":"1515_CR17","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1038\/npp.2009.114","volume":"34","author":"MN Hill","year":"2009","unstructured":"Hill MN, McLaughlin RJ, Morrish AC, Viau V, Floresco SB, Hillard CJ, et al. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 2009, 34: 2733\u20132745.","journal-title":"Neuropsychopharmacology"},{"key":"1515_CR18","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1001\/jamapsychiatry.2019.1427","volume":"76","author":"F Borgan","year":"2019","unstructured":"Borgan F, Laurikainen H, Veronese M, Marques TR, Haaparanta-Solin M, Solin O, et al. In vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis. JAMA Psychiatry 2019, 76: 1074\u20131084.","journal-title":"JAMA Psychiatry"},{"key":"1515_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.schres.2013.06.013","volume":"148","author":"C Muguruza","year":"2013","unstructured":"Muguruza C, Lehtonen M, Aaltonen N, Morentin B, Javier Meana J, Callado LF. Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophr Res 2013, 148: 145\u2013150.","journal-title":"Schizophr Res"},{"key":"1515_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.biopsych.2018.07.009","volume":"84","author":"J Hirvonen","year":"2018","unstructured":"Hirvonen J, Zanotti-Fregonara P, Gorelick DA, Lyoo CH, Rallis-Frutos D, Morse C, et al. Decreased cannabinoid CB1 receptors in male tobacco smokers examined with positron emission tomography. Biol Psychiatry 2018, 84: 715\u2013721.","journal-title":"Biol Psychiatry"},{"key":"1515_CR21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/mp.2011.82","volume":"17","author":"J Hirvonen","year":"2012","unstructured":"Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily Cannabis smokers. Mol Psychiatry 2012, 17: 642\u2013649.","journal-title":"Mol Psychiatry"},{"key":"1515_CR22","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/sj.npp.1300695","volume":"30","author":"P Monteleone","year":"2005","unstructured":"Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 2005, 30: 1216\u20131221.","journal-title":"Neuropsychopharmacology"},{"key":"1515_CR23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.biopsych.2011.05.010","volume":"70","author":"N G\u00e9rard","year":"2011","unstructured":"G\u00e9rard N, Pieters G, Goffin K, Bormans G, Van Laere K. Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biol Psychiatry 2011, 70: 777\u2013784.","journal-title":"Biol Psychiatry"},{"key":"1515_CR24","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3390\/nu10091294","volume":"10","author":"AV Gait\u00e1n","year":"2018","unstructured":"Gait\u00e1n AV, Wood JT, Zhang F, Makriyannis A, Lammi-Keefe CJ. Endocannabinoid metabolome characterization of transitional and mature human milk. Nutrients 2018, 10: 1294.","journal-title":"Nutrients"},{"key":"1515_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127513","volume":"30","author":"Z Chen","year":"2020","unstructured":"Chen Z, Hou L, Gan J, Cai Q, Ye W, Chen J, et al. Synthesis and preliminary evaluation of a novel positron emission tomography (PET) ligand for imaging fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett 2020, 30: 127513.","journal-title":"Bioorg Med Chem Lett"},{"key":"1515_CR26","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1007\/s00259-021-05234-1","volume":"48","author":"M Tian","year":"2021","unstructured":"Tian M, He X, Jin C, He X, Wu S, Zhou R, et al. Transpathology: Molecular imaging-based pathology. Eur J Nucl Med Mol Imaging 2021, 48: 2338\u20132350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1515_CR27","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s43657-023-00108-y","volume":"3","author":"Y Li","year":"2023","unstructured":"Li Y, Li F, Han S, Ning J, Su P, Liu J, et al. Performance of 18F-DCFPyL PET\/CT in primary prostate cancer diagnosis, gleason grading and D\u2019Amico classification: A radiomics-based study. Phenomics 2023, 3: 576\u2013585.","journal-title":"Phenomics"},{"key":"1515_CR28","doi-asserted-by":"crossref","unstructured":"Tan J, Zhang G, Hao J, Cai H, Wu D, Su Z, et al. Progress in the application of molecular imaging in psychiatric disorders. Psychoradiology 2023, 3: kkad020.","DOI":"10.1093\/psyrad\/kkad020"},{"key":"1515_CR29","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1007\/s00259-021-05230-5","volume":"48","author":"K Zhang","year":"2021","unstructured":"Zhang K, Mizuma H, Zhang X, Takahashi K, Jin C, Song F, et al. PET imaging of neural activity, \u03b2-amyloid, and tau in normal brain aging. Eur J Nucl Med Mol Imaging 2021, 48: 3859\u20133871.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1515_CR30","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1021\/acschemneuro.0c00305","volume":"11","author":"C Varlow","year":"2020","unstructured":"Varlow C, Boileau I, Wey HY, Liang SH, Vasdev N. Classics in neuroimaging: Imaging the endocannabinoid pathway with PET. ACS Chem Neurosci 2020, 11: 1855\u20131862.","journal-title":"ACS Chem Neurosci"},{"key":"1515_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1021\/acs.jmedchem.0c01459","volume":"64","author":"L Hou","year":"2021","unstructured":"Hou L, Rong J, Haider A, Ogasawara D, Varlow C, Schafroth MA, et al. Positron emission tomography imaging of the endocannabinoid system: Opportunities and challenges in radiotracer development. J Med Chem 2021, 64: 123\u2013149.","journal-title":"J Med Chem"},{"key":"1515_CR32","first-page":"1689","volume":"47","author":"AG Horti","year":"2006","unstructured":"Horti AG, Fan H, Kuwabara H, Hilton J, Ravert HT, Holt DP, et al. 11C-JHU75528: A radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med 2006, 47: 1689\u20131696.","journal-title":"J Nucl Med"},{"key":"1515_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.nucmedbio.2010.08.001","volume":"38","author":"AA Wilson","year":"2011","unstructured":"Wilson AA, Garcia A, Parkes J, Houle S, Tong J, Vasdev N. 11C] CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography. Nucl Med Biol 2011, 38: 247\u2013253.","journal-title":"Nucl Med Biol"},{"key":"1515_CR34","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00259-010-1411-7","volume":"37","author":"GE Terry","year":"2010","unstructured":"Terry GE, Hirvonen J, Liow JS, Seneca N, Tauscher JT, Schaus JM, et al. Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography. Eur J Nucl Med Mol Imaging 2010, 37: 1499\u20131506.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1515_CR35","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1007\/s00259-021-05671-y","volume":"49","author":"K Takahata","year":"2022","unstructured":"Takahata K, Seki C, Kimura Y, Kubota M, Ichise M, Sano Y, et al. First-in-human in vivo imaging and quantification of monoacylglycerol lipase in the brain: A PET study with 18F-T-401. Eur J Nucl Med Mol Imag 2022, 49: 3150\u20133161.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"1515_CR36","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1021\/acschemneuro.0c00313","volume":"11","author":"S Lahdenpohja","year":"2020","unstructured":"Lahdenpohja S, Rajala NA, Helin JS, Haaparanta-Solin M, Solin O, L\u00f3pez-Pic\u00f3n FR, et al. Ruthenium-mediated 18F-fluorination and preclinical evaluation of a new CB1 receptor imaging agent [18F] FPATPP. ACS Chem Neurosci 2020, 11: 2009\u20132018.","journal-title":"ACS Chem Neurosci"},{"key":"1515_CR37","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/ijms19030833","volume":"19","author":"S Zou","year":"2018","unstructured":"Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int J Mol Sci 2018, 19: 833.","journal-title":"Int J Mol Sci"},{"key":"1515_CR38","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fncel.2016.00294","volume":"10","author":"DA Kendall","year":"2017","unstructured":"Kendall DA, Yudowski GA. Cannabinoid receptors in the central nervous system: Their signaling and roles in disease. Front Cell Neurosci 2017, 10: 294.","journal-title":"Front Cell Neurosci"},{"key":"1515_CR39","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/nm.f.1869","volume":"14","author":"I Katona","year":"2008","unstructured":"Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008, 14: 923\u2013930.","journal-title":"Nat Med"},{"key":"1515_CR40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd1495","volume":"3","author":"V Di Marzo","year":"2004","unstructured":"Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004, 3: 771\u2013784.","journal-title":"Nat Rev Drug Discov"},{"key":"1515_CR41","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","volume":"96","author":"A Ligresti","year":"2016","unstructured":"Ligresti A, De Petrocellis L, Di Marzo V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: Pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev 2016, 96: 1593\u20131659.","journal-title":"Physiol Rev"},{"key":"1515_CR42","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nn.3053","volume":"15","author":"G B\u00e9nard","year":"2012","unstructured":"B\u00e9nard G, Massa F, Puente N, Louren\u00e7o J, Bellocchio L, Soria-G\u00f3mez E, et al. Mitochondrial CB\u2081 receptors regulate neuronal energy metabolism. Nat Neurosci 2012, 15: 558\u2013564.","journal-title":"Nat Neurosci"},{"key":"1515_CR43","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0969-8051(00)00152-9","volume":"27","author":"WB Mathews","year":"2000","unstructured":"Mathews WB, Scheffel U, Finley P, Ravert HT, Frank RA, Rinaldi-Carmona M, et al. Biodistribution of [18F] SR144385 and [18F] SR147963: Selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. Nucl Med Biol 2000, 27: 757\u2013762.","journal-title":"Nucl Med Biol"},{"key":"1515_CR44","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0969-8051(02)00308-6","volume":"29","author":"WB Mathews","year":"2002","unstructured":"Mathews WB, Scheffel U, Rauseo PA, Ravert HT, Frank RA, Ellames GJ, et al. Carbon-11 labeled radioligands for imaging brain cannabinoid receptors. Nucl Med Biol 2002, 29: 671\u2013677.","journal-title":"Nucl Med Biol"},{"key":"1515_CR45","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.neuroimage.2013.09.043","volume":"84","author":"T Tsujikawa","year":"2014","unstructured":"Tsujikawa T, Zoghbi SS, Hong J, Donohue SR, Jenko KJ, Gladding RL, et al. In vitro and in vivo evaluation of (11)C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors. Neuroimage 2014, 84: 733\u2013741.","journal-title":"Neuroimage"},{"key":"1515_CR46","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00259-012-2163-3","volume":"39","author":"C Casteels","year":"2012","unstructured":"Casteels C, Koole M, Celen S, Bormans G, Van Laere K. Preclinical evaluation and quantification of [18F] MK-9470 as a radioligand for PET imaging of the type 1 cannabinoid receptor in rat brain. Eur J Nucl Med Mol Imag 2012, 39: 1467\u20131477.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"1515_CR47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/365061a0","volume":"365","author":"S Munro","year":"1993","unstructured":"Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365: 61\u201365.","journal-title":"Nature"},{"key":"1515_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.828895","volume":"13","author":"H Ishiguro","year":"2022","unstructured":"Ishiguro H, Kibret BG, Horiuchi Y, Onaivi ES. Potential role of cannabinoid type 2 receptors in neuropsychiatric and neurodegenerative disorders. Front Psychiatry 2022, 13: 828895.","journal-title":"Front Psychiatry"},{"key":"1515_CR49","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/syn.20569","volume":"62","author":"A Brusco","year":"2008","unstructured":"Brusco A, Tagliaferro P, Saez T, Onaivi ES. Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus. Synapse 2008, 62: 944\u2013949.","journal-title":"Synapse"},{"key":"1515_CR50","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1126\/science.1115740","volume":"310","author":"MD Van Sickle","year":"2005","unstructured":"Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310: 329\u2013332.","journal-title":"Science"},{"key":"1515_CR51","doi-asserted-by":"publisher","first-page":"17410","DOI":"10.1038\/s41598-017-17796-y","volume":"7","author":"QR Liu","year":"2017","unstructured":"Liu QR, Canseco-Alba A, Zhang HY, Tagliaferro P, Chung M, Dennis E, et al. Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference. Sci Rep 2017, 7: 17410.","journal-title":"Sci Rep"},{"key":"1515_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.866052","volume":"13","author":"A Morcuende","year":"2022","unstructured":"Morcuende A, Garc\u00eda-Guti\u00e9rrez MS, Tambaro S, Nieto E, Manzanares J, Femenia T. Immunomodulatory role of CB2 receptors in emotional and cognitive disorders. Front Psychiatry 2022, 13: 866052.","journal-title":"Front Psychiatry"},{"key":"1515_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.925792","volume":"16","author":"AS Ferranti","year":"2022","unstructured":"Ferranti AS, Foster DJ. Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits. Front Neurosci 2022, 16: 925792.","journal-title":"Front Neurosci"},{"key":"1515_CR54","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1017\/neu.2014.24","volume":"26","author":"LCM Rodrigues","year":"2014","unstructured":"Rodrigues LCM, Gobira PH, de Oliveira AC, Peli\u00e7\u00e3o R, Teixeira AL, Moreira FA, et al. Neuroinflammation as a possible link between cannabinoids and addiction. Acta Neuropsychiatr 2014, 26: 334\u2013346.","journal-title":"Acta Neuropsychiatr"},{"key":"1515_CR55","doi-asserted-by":"crossref","unstructured":"Cortez IL, Rodrigues da Silva N, Guimar\u00e3es FS, Gomes FV. Are CB2 receptors a new target for schizophrenia treatment? Front Psychiatry 2020, 11: 587154.","DOI":"10.3389\/fpsyt.2020.587154"},{"key":"1515_CR56","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/nn.2874","volume":"14","author":"ZX Xi","year":"2011","unstructured":"Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, et al. Brain cannabinoid CB\u2082 receptors modulate cocaine\u2019s actions in mice. Nat Neurosci 2011, 14: 1160\u20131166.","journal-title":"Nat Neurosci"},{"key":"1515_CR57","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s40263-019-00664-w","volume":"33","author":"E Galaj","year":"2019","unstructured":"Galaj E, Xi ZX. Potential of cannabinoid receptor ligands as treatment for substance use disorders. CNS Drugs 2019, 33: 1001\u20131030.","journal-title":"CNS Drugs"},{"key":"1515_CR58","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41401-018-0035-5","volume":"40","author":"R Ni","year":"2019","unstructured":"Ni R, Mu L, Ametamey S. Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system. Acta Pharmacol Sin 2019, 40: 351\u2013357.","journal-title":"Acta Pharmacol Sin"},{"key":"1515_CR59","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s11307-013-0626-y","volume":"15","author":"R Ahmad","year":"2013","unstructured":"Ahmad R, Koole M, Evens N, Serdons K, Verbruggen A, Bormans G, et al. Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [11C]-NE40 in healthy subjects. Mol Imaging Biol 2013, 15: 384\u2013390.","journal-title":"Mol Imaging Biol"},{"key":"1515_CR60","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1007\/s00259-016-3457-7","volume":"43","author":"R Ahmad","year":"2016","unstructured":"Ahmad R, Postnov A, Bormans G, Versijpt J, Vandenbulcke M, Van Laere K. Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging 2016, 43: 2219\u20132227.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1515_CR61","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ejmech.2015.01.028","volume":"92","author":"R Slavik","year":"2015","unstructured":"Slavik R, Herde AM, Bieri D, Weber M, Schibli R, Kr\u00e4mer SD, et al. Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor. Eur J Med Chem 2015, 92: 554\u2013564.","journal-title":"Eur J Med Chem"},{"key":"1515_CR62","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/jnc.13716","volume":"138","author":"R Slavik","year":"2016","unstructured":"Slavik R, Herde AM, Haider A, Kr\u00e4mer SD, Weber M, Schibli R, et al. Discovery of a fluorinated 4-oxo-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2. J Neurochem 2016, 138: 874\u2013886.","journal-title":"J Neurochem"},{"key":"1515_CR63","doi-asserted-by":"publisher","first-page":"10287","DOI":"10.1021\/acs.jmedchem.0c00778","volume":"63","author":"A Haider","year":"2020","unstructured":"Haider A, Gobbi L, Kretz J, Ullmer C, Brink A, Honer M, et al. Identification and preclinical development of a 2, 5, 6-trisubstituted fluorinated pyridine derivative as a radioligand for the positron emission tomography imaging of cannabinoid type 2 receptors. J Med Chem 2020, 63: 10287\u201310306.","journal-title":"J Med Chem"},{"key":"1515_CR64","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1177\/0271678X16685105","volume":"37","author":"G Pottier","year":"2017","unstructured":"Pottier G, G\u00f3mez-Vallejo V, Padro D, Boisgard R, Doll\u00e9 F, Llop J, et al. PET imaging of cannabinoid type 2 receptors with [11C] A-836339 did not evidence changes following neuroinflammation in rats. J Cereb Blood Flow Metab 2017, 37: 1163\u20131178.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1515_CR65","doi-asserted-by":"publisher","first-page":"7840","DOI":"10.1021\/acs.jmedchem.6b00554","volume":"59","author":"RP Moldovan","year":"2016","unstructured":"Moldovan RP, Teodoro R, Gao Y, Deuther-Conrad W, Kranz M, Wang Y, et al. Development of a high-affinity PET radioligand for imaging cannabinoid subtype 2 receptor. J Med Chem 2016, 59: 7840\u20137855.","journal-title":"J Med Chem"},{"key":"1515_CR66","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/bph.14564","volume":"176","author":"B Attili","year":"2019","unstructured":"Attili B, Celen S, Ahamed M, Koole M, Haute CVD, Vanduffel W, et al. Preclinical evaluation of [18 F] MA3: A CB2 receptor agonist radiotracer for PET. Br J Pharmacol 2019, 176: 1481\u20131491.","journal-title":"Br J Pharmacol"},{"key":"1515_CR67","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1460-9568.2004.03428.x","volume":"20","author":"AI Gulyas","year":"2004","unstructured":"Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F, et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 2004, 20: 441\u2013458.","journal-title":"Eur J Neurosci"},{"key":"1515_CR68","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev.biochem.74.082803.133450","volume":"74","author":"MK McKinney","year":"2005","unstructured":"McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 2005, 74: 411\u2013432.","journal-title":"Annu Rev Biochem"},{"key":"1515_CR69","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1089\/can.2021.0237","volume":"8","author":"AD Santoso","year":"2023","unstructured":"Santoso AD, De Ridder D. Fatty acid amide hydrolase: An integrative clinical perspective. Cannabis Cannabinoid Res 2023, 8: 56\u201376.","journal-title":"Cannabis Cannabinoid Res"},{"key":"1515_CR70","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.euroneuro.2015.02.005","volume":"25","author":"CJ Fowler","year":"2015","unstructured":"Fowler CJ. The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs\u2014a practical view. Eur Neuropsychopharmacol 2015, 25: 749\u2013762.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1515_CR71","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.neuropharm.2016.10.007","volume":"113","author":"A Simonnet","year":"2017","unstructured":"Simonnet A, Zamberletti E, Cador M, Rubino T, Caill\u00e9 S. Chronic FAAH inhibition during nicotine abstinence alters habenular CB1 receptor activity and precipitates depressive-like behaviors. Neuropharmacology 2017, 113: 252\u2013259.","journal-title":"Neuropharmacology"},{"key":"1515_CR72","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1021\/acs.jmedchem.6b00538","volume":"60","author":"W Tuo","year":"2017","unstructured":"Tuo W, Leleu-Chavain N, Spencer J, Sansook S, Millet R, Chavatte P. Therapeutic potential of fatty acid amide hydrolase, monoacylglycerol lipase, and N-acylethanolamine acid amidase inhibitors. J Med Chem 2017, 60: 4\u201346.","journal-title":"J Med Chem"},{"key":"1515_CR73","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0074-7742(09)85005-8","volume":"85","author":"S Gaetani","year":"2009","unstructured":"Gaetani S, Dipasquale P, Romano A, Righetti L, Cassano T, Piomelli D, et al. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. Int Rev Neurobiol 2009, 85: 57\u201372.","journal-title":"Int Rev Neurobiol"},{"key":"1515_CR74","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.pain.2004.01.022","volume":"109","author":"AH Lichtman","year":"2004","unstructured":"Lichtman AH, Shelton CC, Advani T, Cravatt BF. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 2004, 109: 319\u2013327.","journal-title":"Pain"},{"key":"1515_CR75","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.biopsych.2011.04.022","volume":"70","author":"A Busquets-Garcia","year":"2011","unstructured":"Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A. Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 2011, 70: 479\u2013486.","journal-title":"Biol Psychiatry"},{"key":"1515_CR76","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/jcbfm.2012.180","volume":"33","author":"PM Rusjan","year":"2013","unstructured":"Rusjan PM, Wilson AA, Mizrahi R, Boileau I, Chavez SE, Lobaugh NJ, et al. Mapping human brain fatty acid amide hydrolase activity with PET. J Cereb Blood Flow Metab 2013, 33: 407\u2013414.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1515_CR77","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12872","volume":"26","author":"MR Jacobson","year":"2021","unstructured":"Jacobson MR, Watts JJ, Da Silva T, Tyndale RF, Rusjan PM, Houle S, et al. Fatty acid amide hydrolase is lower in young Cannabis users. Addict Biol 2021, 26: e12872.","journal-title":"Addict Biol"},{"key":"1515_CR78","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.biopsych.2016.04.012","volume":"80","author":"I Boileau","year":"2016","unstructured":"Boileau I, Mansouri E, Williams B, Le Foll B, Rusjan P, Mizrahi R, et al. Fatty acid amide hydrolase binding in brain of Cannabis users: Imaging with the novel radiotracer [11C] CURB. Biol Psychiatry 2016, 80: 691\u2013701.","journal-title":"Biol Psychiatry"},{"key":"1515_CR79","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41386-020-0606-2","volume":"45","author":"LM Best","year":"2020","unstructured":"Best LM, Williams B, Le Foll B, Mansouri E, Bazinet RP, Lin L, et al. Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: A positron emission tomography study with [C-11] CURB. Neuropsychopharmacology 2020, 45: 1289\u20131296.","journal-title":"Neuropsychopharmacology"},{"key":"1515_CR80","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.biopsych.2020.03.003","volume":"88","author":"JJ Watts","year":"2020","unstructured":"Watts JJ, Jacobson MR, Lalang N, Boileau I, Tyndale RF, Kiang M, et al. Imaging brain fatty acid amide hydrolase in untreated patients with psychosis. Biol Psychiatry 2020, 88: 727\u2013735.","journal-title":"Biol Psychiatry"},{"key":"1515_CR81","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/s41386-020-0731-y","volume":"45","author":"NJ Kolla","year":"2020","unstructured":"Kolla NJ, Mizrahi R, Karas K, Wang C, Bagby RM, McMain S, et al. Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: A [11C] CURB positron emission tomography study. Neuropsychopharmacology 2020, 45: 1834\u20131841.","journal-title":"Neuropsychopharmacology"},{"key":"1515_CR82","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41398-020-01144-2","volume":"11","author":"NJ Kolla","year":"2021","unstructured":"Kolla NJ, Boileau I, Karas K, Watts JJ, Rusjan P, Houle S, et al. Lower amygdala fatty acid amide hydrolase in violent offenders with antisocial personality disorder: An [11C] CURB positron emission tomography study. Transl Psychiatry 2021, 11: 57.","journal-title":"Transl Psychiatry"},{"key":"1515_CR83","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/s41598-022-04789-9","volume":"12","author":"NJ Kolla","year":"2022","unstructured":"Kolla NJ, Boileau I, Michael Bagby R. Higher trait neuroticism is associated with greater fatty acid amide hydrolase binding in borderline and antisocial personality disorders. Sci Rep 2022, 12: 1126.","journal-title":"Sci Rep"},{"key":"1515_CR84","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bmc.2015.12.026","volume":"24","author":"Y Shimoda","year":"2016","unstructured":"Shimoda Y, Fujinaga M, Hatori A, Yui J, Zhang Y, Nengaki N, et al. N-(3, 4-Dimethylisoxazol-5-yl)piperazine-4-[4-(2-fluoro-4-[(11)C] methylphenyl)thiazol-2-yl]-1-carboxamide: A promising positron emission tomography ligand for fatty acid amide hydrolase. Bioorg Med Chem 2016, 24: 627\u2013634.","journal-title":"Bioorg Med Chem"},{"key":"1515_CR85","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1021\/cn500269g","volume":"6","author":"K Kumata","year":"2015","unstructured":"Kumata K, Yui J, Hatori A, Maeda J, Xie L, Ogawa M, et al. Development of [(11)C] MFTC for PET imaging of fatty acid amide hydrolase in rat and monkey brains. ACS Chem Neurosci 2015, 6: 339\u2013346.","journal-title":"ACS Chem Neurosci"},{"key":"1515_CR86","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.nucmedbio.2013.04.008","volume":"40","author":"JW Hicks","year":"2013","unstructured":"Hicks JW, Parkes J, Sadovski O, Tong J, Houle S, Vasdev N, et al. Synthesis and preclinical evaluation of [11C-carbonyl] PF-04457845 for neuroimaging of fatty acid amide hydrolase. Nucl Med Biol 2013, 40: 740\u2013746.","journal-title":"Nucl Med Biol"},{"key":"1515_CR87","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.nucmedbio.2012.03.011","volume":"39","author":"MB Skaddan","year":"2012","unstructured":"Skaddan MB, Zhang L, Johnson DS, Zhu A, Zasadny KR, Coelho RV, et al. The synthesis and in vivo evaluation of [18F] PF-9811: A novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH). Nucl Med Biol 2012, 39: 1058\u20131067.","journal-title":"Nucl Med Biol"},{"key":"1515_CR88","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1016\/j.bmc.2013.04.077","volume":"21","author":"O Sadovski","year":"2013","unstructured":"Sadovski O, Hicks JW, Parkes J, Raymond R, Nobrega J, Houle S, et al. Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase. Bioorg Med Chem 2013, 21: 4351\u20134357.","journal-title":"Bioorg Med Chem"},{"key":"1515_CR89","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1021\/mp500316h","volume":"11","author":"BH Rotstein","year":"2014","unstructured":"Rotstein BH, Wey HY, Shoup TM, Wilson AA, Liang SH, Hooker JM, et al. PET imaging of fatty acid amide hydrolase with [(18)F] DOPP in nonhuman Primates. Mol Pharm 2014, 11: 3832\u20133838.","journal-title":"Mol Pharm"},{"key":"1515_CR90","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11307-014-0789-1","volume":"17","author":"TM Shoup","year":"2015","unstructured":"Shoup TM, Bonab AA, Wilson AA, Vasdev N. Synthesis and preclinical evaluation of [1\u2078F] FCHC for neuroimaging of fatty acid amide hydrolase. Mol Imaging Biol 2015, 17: 257\u2013263.","journal-title":"Mol Imaging Biol"},{"key":"1515_CR91","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/jlcr.3528","volume":"61","author":"K Dahl","year":"2018","unstructured":"Dahl K, Collier TL, Cheng R, Zhang X, Sadovski O, Liang SH, et al. \u201cIn-loop\u201d [11 C] CO2 fixation: Prototype and proof of concept. J Labelled Comp Radiopharm 2018, 61: 252\u2013262.","journal-title":"J Labelled Comp Radiopharm"},{"key":"1515_CR92","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1021\/ml4000996","volume":"4","author":"P Liu","year":"2013","unstructured":"Liu P, Hamill TG, Chioda M, Chobanian H, Fung S, Guo Y, et al. Discovery of MK-3168: A PET tracer for imaging brain fatty acid amide hydrolase. ACS Med Chem Lett 2013, 4: 509\u2013513.","journal-title":"ACS Med Chem Lett"},{"key":"1515_CR93","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1021\/acschemneuro.5b00248","volume":"7","author":"L Wang","year":"2016","unstructured":"Wang L, Yui J, Wang Q, Zhang Y, Mori W, Shimoda Y, et al. Synthesis and preliminary PET imaging studies of a FAAH radiotracer ([11C] MPPO) based on \u03b1-ketoheterocyclic scaffold. ACS Chem Neurosci 2016, 7: 109\u2013118.","journal-title":"ACS Chem Neurosci"},{"key":"1515_CR94","doi-asserted-by":"publisher","first-page":"10819","DOI":"10.1073\/pnas.152334899","volume":"99","author":"TP Dinh","year":"2002","unstructured":"Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002, 99: 10819\u201310824.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1515_CR95","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/cells11030471","volume":"11","author":"A Papa","year":"2022","unstructured":"Papa A, Pasquini S, Contri C, Gemma S, Campiani G, Butini S, et al. Polypharmacological approaches for CNS diseases: Focus on endocannabinoid degradation inhibition. Cells 2022, 11: 471.","journal-title":"Cells"},{"key":"1515_CR96","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1021\/cr0782067","volume":"108","author":"K Ahn","year":"2008","unstructured":"Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008, 108: 1687\u20131707.","journal-title":"Chem Rev"},{"key":"1515_CR97","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.3390\/ijms23094764","volume":"23","author":"D Navarro","year":"2022","unstructured":"Navarro D, Gasparyan A, Navarrete F, Torregrosa AB, Rubio G, Mar\u00edn-Mayor M, et al. Molecular alterations of the endocannabinoid system in psychiatric disorders. Int J Mol Sci 2022, 23: 4764.","journal-title":"Int J Mol Sci"},{"key":"1515_CR98","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Rivera A, Fetcho RN, Birmingham L, Jiu JX, Yang R, Foord C, et al. Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. bioRxiv 2024: 2024.04.02.585967.","DOI":"10.1101\/2024.04.02.585967"},{"key":"1515_CR99","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.3390\/molecules26185668","volume":"26","author":"A Zanfirescu","year":"2021","unstructured":"Zanfirescu A, Ungurianu A, Mihai DP, Radulescu D, Nitulescu GM. Targeting monoacylglycerol lipase in pursuit of therapies for neurological and neurodegenerative diseases. Molecules 2021, 26: 5668.","journal-title":"Molecules"},{"key":"1515_CR100","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.pnpbp.2012.04.002","volume":"38","author":"A Giuffrida","year":"2012","unstructured":"Giuffrida A, Seillier A. New insights on endocannabinoid transmission in psychomotor disorders. Prog Neuropsychopharmacol Biol Psychiatry 2012, 38: 51\u201358.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1515_CR101","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1126\/science.1209200","volume":"334","author":"DK Nomura","year":"2011","unstructured":"Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MCG, et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011, 334: 809\u2013813.","journal-title":"Science"},{"key":"1515_CR102","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.apsb.2019.10.006","volume":"10","author":"H Deng","year":"2020","unstructured":"Deng H, Li W. Monoacylglycerol lipase inhibitors: Modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders. Acta Pharm Sin B 2020, 10: 582\u2013602.","journal-title":"Acta Pharm Sin B"},{"key":"1515_CR103","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.nucmedbio.2014.05.001","volume":"41","author":"JW Hicks","year":"2014","unstructured":"Hicks JW, Parkes J, Tong J, Houle S, Vasdev N, Wilson AA. Radiosynthesis and ex vivo evaluation of [(11)C-carbonyl] carbamate- and urea-based monoacylglycerol lipase inhibitors. Nucl Med Biol 2014, 41: 688\u2013694.","journal-title":"Nucl Med Biol"},{"key":"1515_CR104","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.7150\/thno.15257","volume":"6","author":"L Wang","year":"2016","unstructured":"Wang L, Mori W, Cheng R, Yui J, Hatori A, Ma L, et al. Synthesis and preclinical evaluation of sulfonamido-based [(11)C-carbonyl]-carbamates and ureas for imaging monoacylglycerol lipase. Theranostics 2016, 6: 1145\u20131159.","journal-title":"Theranostics"},{"key":"1515_CR105","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1021\/acschemneuro.5b00293","volume":"7","author":"C Wang","year":"2016","unstructured":"Wang C, Placzek MS, Van de Bittner GC, Schroeder FA, Hooker JM. A novel radiotracer for imaging monoacylglycerol lipase in the brain using positron emission tomography. ACS Chem Neurosci 2016, 7: 484\u2013489.","journal-title":"ACS Chem Neurosci"},{"key":"1515_CR106","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.neuroimage.2018.05.015","volume":"176","author":"T Yamasaki","year":"2018","unstructured":"Yamasaki T, Mori W, Zhang Y, Hatori A, Fujinaga M, Wakizaka H, et al. First demonstration of in vivo mapping for regional brain monoacylglycerol lipase using PET with [11C] SAR127303. Neuroimage 2018, 176: 313\u2013320.","journal-title":"Neuroimage"},{"key":"1515_CR107","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejmech.2017.04.066","volume":"136","author":"M Ahamed","year":"2017","unstructured":"Ahamed M, Attili B, van Veghel D, Ooms M, Berben P, Celen S, et al. Synthesis and preclinical evaluation of [11C] MA-PB-1 for in vivo imaging of brain monoacylglycerol lipase (MAGL). Eur J Med Chem 2017, 136: 104\u2013113.","journal-title":"Eur J Med Chem"},{"key":"1515_CR108","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1021\/acs.jmedchem.7b01400","volume":"61","author":"R Cheng","year":"2018","unstructured":"Cheng R, Mori W, Ma L, Alhouayek M, Hatori A, Zhang Y, et al. In vitro and in vivo evaluation of 11C-labeled azetidinecarboxylates for imaging monoacylglycerol lipase by PET imaging studies. J Med Chem 2018, 61: 2278\u20132291.","journal-title":"J Med Chem"},{"key":"1515_CR109","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1021\/acs.jmedchem.8b01778","volume":"62","author":"Z Chen","year":"2019","unstructured":"Chen Z, Mori W, Deng X, Cheng R, Ogasawara D, Zhang G, et al. Design, synthesis, and evaluation of reversible and irreversible monoacylglycerol lipase positron emission tomography (PET) tracers using a \u201ctail switching\u201d strategy on a piperazinyl azetidine skeleton. J Med Chem 2019, 62: 3336\u20133353.","journal-title":"J Med Chem"},{"key":"1515_CR110","doi-asserted-by":"publisher","first-page":"8532","DOI":"10.1021\/acs.jmedchem.9b00847","volume":"62","author":"L Zhang","year":"2019","unstructured":"Zhang L, Butler CR, Maresca KP, Takano A, Nag S, Jia Z, et al. Identification and development of an irreversible monoacylglycerol lipase (MAGL) positron emission tomography (PET) radioligand with high specificity. J Med Chem 2019, 62: 8532\u20138543.","journal-title":"J Med Chem"},{"key":"1515_CR111","doi-asserted-by":"publisher","first-page":"8866","DOI":"10.1021\/acs.jmedchem.9b00936","volume":"62","author":"Z Chen","year":"2019","unstructured":"Chen Z, Mori W, Fu H, Schafroth MA, Hatori A, Shao T, et al. Design, synthesis, and evaluation of 18F-labeled monoacylglycerol lipase inhibitors as novel positron emission tomography probes. J Med Chem 2019, 62: 8866\u20138872.","journal-title":"J Med Chem"},{"key":"1515_CR112","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1177\/0271678X211058285","volume":"42","author":"Y Hattori","year":"2022","unstructured":"Hattori Y, Seki C, Maeda J, Nagai Y, Aoyama K, Zhang MR, et al. Quantification of monoacylglycerol lipase and its occupancy by an exogenous ligand in Rhesus monkey brains using [18F] T-401 and PET. J Cereb Blood Flow Metab 2022, 42: 656\u2013666.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1515_CR113","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.apsb.2021.07.007","volume":"12","author":"T Shao","year":"2022","unstructured":"Shao T, Chen Z, Rong J, Belov V, Chen J, Jeyarajan A, et al. 18F] MAGL-4-11 positron emission tomography molecular imaging of monoacylglycerol lipase changes in preclinical liver fibrosis models. Acta Pharm Sin B 2022, 12: 308\u2013315.","journal-title":"Acta Pharm Sin B"},{"key":"1515_CR114","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1038\/s41401-022-00912-8","volume":"43","author":"R Cheng","year":"2022","unstructured":"Cheng R, Fujinaga M, Yang J, Rong J, Haider A, Ogasawara D, et al. A novel monoacylglycerol lipase-targeted 18F-labeled probe for positron emission tomography imaging of brown adipose tissue in the energy network. Acta Pharmacol Sin 2022, 43: 3002\u20133010.","journal-title":"Acta Pharmacol Sin"},{"key":"1515_CR115","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","volume":"64","author":"R Mechoulam","year":"2013","unstructured":"Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol 2013, 64: 21\u201347.","journal-title":"Annu Rev Psychol"},{"key":"1515_CR116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050141","volume":"5","author":"L Degenhardt","year":"2008","unstructured":"Degenhardt L, Chiu WT, Sampson N, Kessler RC, Anthony JC, Angermeyer M, et al. Toward a global view of alcohol, tobacco, Cannabis, and cocaine use: Findings from the WHO World Mental Health Surveys. PLoS Med 2008, 5: e141.","journal-title":"PLoS Med"},{"key":"1515_CR117","doi-asserted-by":"publisher","first-page":"187","DOI":"10.7326\/M17-1548","volume":"168","author":"D Ravi","year":"2018","unstructured":"Ravi D, Ghasemiesfe M, Korenstein D, Cascino T, Keyhani S. Associations between marijuana use and cardiovascular risk factors and outcomes: A systematic review. Ann Intern Med 2018, 168: 187\u2013194.","journal-title":"Ann Intern Med"},{"key":"1515_CR118","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1038\/s41467-020-20121-3","volume":"11","author":"CJ Dubois","year":"2020","unstructured":"Dubois CJ, Fawcett-Patel J, Katzman PA, Liu SJ. Inhibitory neurotransmission drives endocannabinoid degradation to promote memory consolidation. Nat Commun 2020, 11: 6407.","journal-title":"Nat Commun"},{"key":"1515_CR119","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.pbb.2005.01.028","volume":"81","author":"S Gonz\u00e1lez","year":"2005","unstructured":"Gonz\u00e1lez S, Cebeira M, Fern\u00e1ndez-Ruiz J. Cannabinoid tolerance and dependence: A review of studies in laboratory animals. Pharmacol Biochem Behav 2005, 81: 300\u2013318.","journal-title":"Pharmacol Biochem Behav"},{"key":"1515_CR120","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/adb.12116","volume":"20","author":"J Ceccarini","year":"2015","unstructured":"Ceccarini J, Kuepper R, Kemels D, van Os J, Henquet C, Van Laere K. 18F] MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic Cannabis users. Addict Biol 2015, 20: 357\u2013367.","journal-title":"Addict Biol"},{"key":"1515_CR121","first-page":"60","volume":"1","author":"DC D\u2019Souza","year":"2016","unstructured":"D\u2019Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, et al. Rapid changes in cannabinoid 1 receptor availability in Cannabis-dependent male subjects after abstinence from Cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging 2016, 1: 60\u201367.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"1515_CR122","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13061","volume":"26","author":"TR Spindle","year":"2021","unstructured":"Spindle TR, Kuwabara H, Eversole A, Nandi A, Vandrey R, Antoine DG, et al. Brain imaging of cannabinoid type I (CB1) receptors in women with Cannabis use disorder and male and female healthy controls. Addict Biol 2021, 26: e13061.","journal-title":"Addict Biol"},{"key":"1515_CR123","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.pnpbp.2015.06.011","volume":"65","author":"AN Henderson-Redmond","year":"2016","unstructured":"Henderson-Redmond AN, Guindon J, Morgan DJ. Roles for the endocannabinoid system in ethanol-motivated behavior. Prog Neuropsychopharmacol Biol Psychiatry 2016, 65: 330\u2013339.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1515_CR124","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41398-021-01337-3","volume":"11","author":"R Fu","year":"2021","unstructured":"Fu R, Tang Y, Li W, Ren Z, Li D, Zheng J, et al. Endocannabinoid signaling in the lateral habenula regulates pain and alcohol consumption. Transl Psychiatry 2021, 11: 220.","journal-title":"Transl Psychiatry"},{"key":"1515_CR125","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/bs.irn.2015.10.004","volume":"125","author":"C Sagheddu","year":"2015","unstructured":"Sagheddu C, Muntoni AL, Pistis M, Melis M. Endocannabinoid signaling in motivation, reward, and addiction: Influences on mesocorticolimbic dopamine function. Int Rev Neurobiol 2015, 125: 257\u2013302.","journal-title":"Int Rev Neurobiol"},{"key":"1515_CR126","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1111\/j.1530-0277.2012.01815.x","volume":"36","author":"A Neumeister","year":"2012","unstructured":"Neumeister A, Normandin MD, Murrough JW, Henry S, Bailey CR, Luckenbaugh DA, et al. Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence. Alcohol Clin Exp Res 2012, 36: 2104\u20132109.","journal-title":"Alcohol Clin Exp Res"},{"key":"1515_CR127","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/mp.2012.100","volume":"18","author":"J Hirvonen","year":"2013","unstructured":"Hirvonen J, Zanotti-Fregonara P, Umhau JC, George DT, Rallis-Frutos D, Lyoo CH, et al. Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography. Mol Psychiatry 2013, 18: 916\u2013921.","journal-title":"Mol Psychiatry"},{"key":"1515_CR128","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/archpsyc.65.7.841","volume":"65","author":"KE Hutchison","year":"2008","unstructured":"Hutchison KE, Haughey H, Niculescu M, Schacht J, Kaiser A, Stitzel J, et al. The incentive salience of alcohol: Translating the effects of genetic variant in CNR1. Arch Gen Psychiatry 2008, 65: 841\u2013850.","journal-title":"Arch Gen Psychiatry"},{"key":"1515_CR129","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1523\/JNEUROSCI.0849-13.2014","volume":"34","author":"J Ceccarini","year":"2014","unstructured":"Ceccarini J, Hompes T, Verhaeghen A, Casteels C, Peuskens H, Bormans G, et al. Changes in cerebral CB1 receptor availability after acute and chronic alcohol abuse and monitored abstinence. J Neurosci 2014, 34: 2822\u20132831.","journal-title":"J Neurosci"},{"key":"1515_CR130","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1056\/NEJMra012941","volume":"346","author":"R Yehuda","year":"2002","unstructured":"Yehuda R. Post-traumatic stress disorder. N Engl J Med 2002, 346: 108\u2013114.","journal-title":"N Engl J Med"},{"key":"1515_CR131","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.phrs.2016.07.024","volume":"111","author":"A Berardi","year":"2016","unstructured":"Berardi A, Schelling G, Campolongo P. The endocannabinoid system and post traumatic stress disorder (PTSD): From preclinical findings to innovative therapeutic approaches in clinical settings. Pharmacol Res 2016, 111: 668\u2013678.","journal-title":"Pharmacol Res"},{"key":"1515_CR132","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.biopsych.2021.07.019","volume":"91","author":"LM Mayo","year":"2022","unstructured":"Mayo LM, Rabinak CA, Hill MN, Heilig M. Targeting the endocannabinoid system in the treatment of posttraumatic stress disorder: A promising case of preclinical-clinical translation? Biol Psychiatry 2022, 91: 262\u2013272.","journal-title":"Biol Psychiatry"},{"key":"1515_CR133","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/mp.2013.61","volume":"18","author":"A Neumeister","year":"2013","unstructured":"Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study. Mol Psychiatry 2013, 18: 1034\u20131040.","journal-title":"Mol Psychiatry"},{"key":"1515_CR134","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","volume":"399","author":"S Jauhar","year":"2022","unstructured":"Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet 2022, 399: 473\u2013486.","journal-title":"Schizophrenia. Lancet"},{"key":"1515_CR135","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jamapsychiatry.2019.0970","volume":"76","author":"A Minichino","year":"2019","unstructured":"Minichino A, Senior M, Brondino N, Zhang SH, Godwlewska BR, Burnet PWJ, et al. Measuring disturbance of the endocannabinoid system in psychosis: A systematic review and meta-analysis. JAMA Psychiatry 2019, 76: 914\u2013923.","journal-title":"JAMA Psychiatry"},{"key":"1515_CR136","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/npp.2010.75","volume":"35","author":"SM Eggan","year":"2010","unstructured":"Eggan SM, Stoyak SR, Verrico CD, Lewis DA. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology 2010, 35: 2060\u20132071.","journal-title":"Neuropsychopharmacology"},{"key":"1515_CR137","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pnpbp.2003.11.005","volume":"28","author":"K Zavitsanou","year":"2004","unstructured":"Zavitsanou K, Garrick T, Huang XF. Selective antagonist [3H] SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28: 355\u2013360.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1515_CR138","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.neuroimage.2010.04.034","volume":"52","author":"DF Wong","year":"2010","unstructured":"Wong DF, Kuwabara H, Horti AG, Raymont V, Brasic J, Guevara M, et al. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C] OMAR. Neuroimage 2010, 52: 1505\u20131513.","journal-title":"Neuroimage"},{"key":"1515_CR139","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.neuroimage.2013.04.052","volume":"79","author":"J Ceccarini","year":"2013","unstructured":"Ceccarini J, De Hert M, Van Winkel R, Peuskens J, Bormans G, Kranaster L, et al. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage 2013, 79: 304\u2013312.","journal-title":"Neuroimage"},{"key":"1515_CR140","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.biopsych.2015.08.021","volume":"79","author":"M Ranganathan","year":"2016","unstructured":"Ranganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P, et al. Reduced brain cannabinoid receptor availability in schizophrenia. Biol Psychiatry 2016, 79: 997\u20131005.","journal-title":"Biol Psychiatry"},{"key":"1515_CR141","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00406-020-01191-2","volume":"271","author":"F Borgan","year":"2021","unstructured":"Borgan F, Veronese M, Reis Marques T, Lythgoe DJ, Howes O. Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: A multi-modal PET and 1H-MRS study. Eur Arch Psychiatry Clin Neurosci 2021, 271: 677\u2013687.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1515_CR142","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1038\/s41380-019-0619-6","volume":"26","author":"F Borgan","year":"2021","unstructured":"Borgan F, O\u2019Daly O, Veronese M, Reis Marques T, Laurikainen H, Hietala J, et al. The neural and molecular basis of working memory function in psychosis: A multimodal PET-fMRI study. Mol Psychiatry 2021, 26: 4464\u20134474.","journal-title":"Mol Psychiatry"},{"key":"1515_CR143","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0140-6736(20)30059-3","volume":"395","author":"J Treasure","year":"2020","unstructured":"Treasure J, Duarte TA, Schmidt U. Eating disorders. Lancet 2020, 395: 899\u2013911.","journal-title":"Lancet"},{"key":"1515_CR144","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nn1457","volume":"8","author":"V Di Marzo","year":"2005","unstructured":"Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005, 8: 585\u2013589.","journal-title":"Nat Neurosci"},{"key":"1515_CR145","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0140-6736(07)60033-6","volume":"369","author":"RS Padwal","year":"2007","unstructured":"Padwal RS, Majumdar SR. Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Lancet 2007, 369: 71\u201377.","journal-title":"Lancet"},{"key":"1515_CR146","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","volume":"370","author":"R Christensen","year":"2007","unstructured":"Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet 2007, 370: 1706\u20131713.","journal-title":"Lancet"},{"key":"1515_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107477","volume":"208","author":"R Cinar","year":"2020","unstructured":"Cinar R, Iyer MR, Kunos G. The therapeutic potential of second and third generation CB1R antagonists. Pharmacol Ther 2020, 208: 107477.","journal-title":"Pharmacol Ther"},{"key":"1515_CR148","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1038\/s41380-021-01428-z","volume":"27","author":"C Berland","year":"2022","unstructured":"Berland C, Castel J, Terrasi R, Montalban E, Foppen E, Martin C, et al. Identification of an endocannabinoid gut-brain vagal mechanism controlling food reward and energy homeostasis. Mol Psychiatry 2022, 27: 2340\u20132354.","journal-title":"Mol Psychiatry"},{"key":"1515_CR149","doi-asserted-by":"publisher","first-page":"E9125","DOI":"10.1073\/pnas.1705753114","volume":"114","author":"DC Castro","year":"2017","unstructured":"Castro DC, Berridge KC. Opioid and orexin hedonic hotspots in rat orbitofrontal cortex and Insula. Proc Natl Acad Sci U S A 2017, 114: E9125\u2013E9134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1515_CR150","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41467-018-03848-y","volume":"9","author":"L Nummenmaa","year":"2018","unstructured":"Nummenmaa L, Saanijoki T, Tuominen L, Hirvonen J, Tuulari JJ, Nuutila P, et al. \u03bc-opioid receptor system mediates reward processing in humans. Nat Commun 2018, 9: 1500.","journal-title":"Nat Commun"},{"key":"1515_CR151","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s00259-013-2522-8","volume":"41","author":"C Casteels","year":"2014","unstructured":"Casteels C, G\u00e9rard N, van Kuyck K, Pottel L, Nuttin B, Bormans G, et al. Small animal PET imaging of the type 1 cannabinoid receptor in a rodent model for anorexia nervosa. Eur J Nucl Med Mol Imaging 2014, 41: 308\u2013321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1515_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.118","volume":"6","author":"J Ceccarini","year":"2016","unstructured":"Ceccarini J, Weltens N, Ly HG, Tack J, Van Oudenhove L, Van Laere K. Association between cerebral cannabinoid 1 receptor availability and body mass index in patients with food intake disorders and healthy subjects: A [(18)F] MK-9470 PET study. Transl Psychiatry 2016, 6: e853.","journal-title":"Transl Psychiatry"},{"key":"1515_CR153","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41398-021-01559-5","volume":"11","author":"T Kantonen","year":"2021","unstructured":"Kantonen T, Karjalainen T, Pekkarinen L, Isoj\u00e4rvi J, Kalliokoski K, Kaasinen V, et al. Cerebral \u03bc-opioid and CB1 receptor systems have distinct roles in human feeding behavior. Transl Psychiatry 2021, 11: 442.","journal-title":"Transl Psychiatry"},{"key":"1515_CR154","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jpsychires.2023.03.045","volume":"162","author":"H Xu","year":"2023","unstructured":"Xu H, Owens MM, Farncombe T, Noseworthy M, MacKillop J. Molecular brain differences and Cannabis involvement: A systematic review of positron emission tomography studies. J Psychiatr Res 2023, 162: 44\u201356.","journal-title":"J Psychiatr Res"},{"key":"1515_CR155","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1177\/02698811221148604","volume":"37","author":"A Bassir Nia","year":"2023","unstructured":"Bassir Nia A, Gibson CL, Spriggs SA, Jankowski SE, DeFrancisco D, Swift A, et al. Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis. J Psychopharmacol 2023, 37: 484\u2013489.","journal-title":"J Psychopharmacol"},{"key":"1515_CR156","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.biopsych.2022.11.022","volume":"94","author":"LM Best","year":"2023","unstructured":"Best LM, Hendershot CS, Buckman JF, Jagasar S, McPhee MD, Muzumdar N, et al. Association between fatty acid amide hydrolase and alcohol response phenotypes: A positron emission tomography imaging study with [11C] CURB in heavy-drinking youth. Biol Psychiatry 2023, 94: 405\u2013415.","journal-title":"Biol Psychiatry"},{"key":"1515_CR157","doi-asserted-by":"crossref","unstructured":"Sui J, Zhi D, Calhoun VD. Data-driven multimodal fusion: Approaches and applications in psychiatric research. Psychoradiology 2023, 3: kkad026.","DOI":"10.1093\/psyrad\/kkad026"},{"key":"1515_CR158","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1021\/acs.jmedchem.2c01485","volume":"66","author":"K Mardon","year":"2023","unstructured":"Mardon K, Patel JZ, Savinainen JR, Stimson DHR, Oyagawa CRM, Grimsey NL, et al. Utilizing PET and MALDI imaging for discovery of a targeted probe for brain endocannabinoid \u03b1\/\u03b2-hydrolase domain 6 (ABHD6). J Med Chem 2023, 66: 538\u2013552.","journal-title":"J Med Chem"},{"key":"1515_CR159","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.2174\/13816128113196660735","volume":"20","author":"CJ Hillard","year":"2014","unstructured":"Hillard CJ, Liu QS. Endocannabinoid signaling in the etiology and treatment of major depressive illness. Curr Pharm Des 2014, 20: 3795\u20133811.","journal-title":"Curr Pharm Des"}],"container-title":["Neuroscience Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-025-01515-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12264-025-01515-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-025-01515-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:03:31Z","timestamp":1770278611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12264-025-01515-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":159,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1007\/s12264-025-01515-z","relation":{},"ISSN":["1673-7067","1995-8218"],"issn-type":[{"value":"1673-7067","type":"print"},{"value":"1995-8218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This review article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}